As of November 6, 2026, Kiniksa Pharmaceuticals International, plc is a publicly traded company (Nasdaq: KNSA). The largest holder reporting an active stake on Schedule 13D is Baker Bros. Advisors LP, at 7%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Fidelity (FMR) (14.8%), Rubric Capital Management LP (7.37%), BlackRock (5.5%) (Schedule 13D/A, May 26, 2026).
Is this your company?
About to sign with, pay or invest in Kiniksa Pharmaceuticals International, plc? See the free Snapshot first.
Free to see. No signup.
Is Kiniksa Pharmaceuticals International, plc a real, registered company?
- Kiniksa Pharmaceuticals International, plc files with the SEC under CIK 1730430 (its SEC filings).
- Its shares are listed under the ticker KNSA on Nasdaq (SEC company record).
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Kiniksa Pharmaceuticals International, plc in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Ross Moat, Chief Operating Officer (Form 8-K filed 2026-10-22). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-07-29).
Who are Kiniksa Pharmaceuticals International, plc's owners and officers?
Kiniksa Pharmaceuticals International, plc: industry Pharmaceutical Preparations (Form D, 2026-10-22).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-07-29 | Blackrock, Inc. | 5.5% |
| Schedule 13D/A, 2026-05-26 | Baker Bros. Advisors LP | 7% |
| Schedule 13G/A, 2026-05-06 | Fmr LLC | 14.8% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G, 2026-03-06 | Fmr LLC | 10.6% |
| Schedule 13G/A, 2026-02-13 | Rubric Capital Management LP | 7.37% |
| Schedule 13G/A, 2025-10-31 | The Vanguard Group | 7.04% |
| Schedule 13G/A, 2025-07-17 | Blackrock, Inc. | 1% |
| Schedule 13G/A, 2025-07-09 | Rubric Capital Management LP | 9.24% |
Questions about who owns Kiniksa Pharmaceuticals International, plc
Who owns Kiniksa Pharmaceuticals International, plc?
On this page, 4 holders' latest ownership filings report 5% or more of Kiniksa Pharmaceuticals International, plc: Fmr LLC (14.8%, Schedule 13G/A, filed 2026-05-06), Rubric Capital Management LP (7.37%, Schedule 13G/A, filed 2026-02-13), Baker Bros. Advisors LP (7%, Schedule 13D/A, filed 2026-05-26) and Blackrock, Inc. (5.5%, Schedule 13G, filed 2026-07-29).
Who are the largest shareholders of Kiniksa Pharmaceuticals International, plc?
By the share each holder's latest filing reports, the largest holders of Kiniksa Pharmaceuticals International, plc on this page are Fmr LLC (14.8%), Rubric Capital Management LP (7.37%) and Baker Bros. Advisors LP (7%).
When did Fmr LLC buy into Kiniksa Pharmaceuticals International, plc?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2026-03-06, reporting 10.6%; its latest, Schedule 13G/A filed 2026-05-06, reports 14.8%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Kiniksa Pharmaceuticals International, plc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Kiniksa Pharmaceuticals International, plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kiniksa Pharmaceuticals International, plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-22 | Ross Moat | Chief Operating Officer | appointed | |
| Form 8-K, 2026-05-01 | Eben Tessari | Chief Strategy Officer | departed | |
| Form 8-K, 2026-05-01 | Eben Tessari | departed |
Which insiders own Kiniksa Pharmaceuticals International, plc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 2,759,734 shares, 14,840 held directly and 2,744,894 indirectly, on a joint filing (Form 4, 2026-06-02).
- Baker Bros. Advisors LP, a director: 2,759,734 shares, 14,840 held directly and 2,744,894 indirectly, on a joint filing (Form 4, 2026-06-02).
- Baker Brothers Life Sciences LP, a director: 2,759,734 shares, 14,840 held directly and 2,744,894 indirectly, on a joint filing (Form 4, 2026-06-02).
- 667, L.P., a director: 2,759,734 shares, 14,840 held directly and 2,744,894 indirectly, on a joint filing (Form 4, 2026-06-02).
- , a director: 2,759,734 shares, 14,840 held directly and 2,744,894 indirectly, on a joint filing (Form 4, 2026-06-02).
Shares only: the company's cover page does not give one share count for a single class, so no percentage is worked out.
How much has Kiniksa Pharmaceuticals International, plc raised?
No fundraising or offering filing from Kiniksa Pharmaceuticals International, plc is on file with us.
Keep reading
More on Kiniksa Pharmaceuticals International, plc and the records around it.
Kiniksa Pharmaceuticals International, plc elsewhere on the record
- 5%+ stake filings Jul 2026
- Leadership changes May 2026
Companies that share a holder
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
- Rubric Capital Management LP also filed stake reports on 32 other companies: ARDELYX, INC. (Aug 2026), Enovis Corporation (Aug 2026), MeiraGTx Holdings plc (Aug 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/kiniksa-pharmaceuticals-international